Updated on 28 December 2014
Accenture has also formed a Life Sciences Cloud Coalition with pharmaceutical giants including Eisai, Merck and Pfizer, aiming to bring about innovation and digitally support various R&D functions thereby accelerating drug discovery process while maintaining quality and low costs.
Mr Kevin Julian, MD, Accenture Accelerated R&D Services, spoke exclusively to BioSpectrum's Raj Gunashekar, sharing his views on how the cloud can improve patient outcomes, bolster R&D efficiency, and the future of cloud in Life Sciences organizations.
Q: Tell us the uniqueness of Accenture Life Sciences Cloud.
Mr Kevin Julian: This one started with a client need. One of our clients made a strategic decision to externalize R&D, which prompted the need for a technology platform to aggregate and analyze data from a variety of sources.
Accenture and Oracle partnered to address the client need, and the result of this collaboration laid the foundation of the ALSC.
There are several unique aspects to it including: